VC005

DRUG3 trials

Sponsors

Jiangsu vcare pharmaceutical technology co., LTD

Conditions

Atopic DermatitisAtopic Dermatitis (AD)

Phase 1

Safety, Tolerance and Pharmacokinetics Clinical Study of VC005 in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis

CompletedNCT06009094

Jiangsu vcare pharmaceutical technology co., LTDAtopic Dermatitis

Start: 2023-07-27End: 2024-05-23Updated: 2024-12-10

Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild to Moderate Atopic Dermatitis

CompletedNCT07329101

Jiangsu vcare pharmaceutical technology co., LTDAtopic Dermatitis (AD)

Start: 2025-11-11End: 2026-02-28Updated: 2026-04-13

Phase 3

Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis

RecruitingNCT07592585

Jiangsu vcare pharmaceutical technology co., LTDAtopic Dermatitis

Start: 2026-05-12End: 2028-05-30Target: 360Updated: 2026-07-07